Charleston, SC -- (SBWIRE) -- 09/19/2013 -- The Team of advisers at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer. Have a look at: Growlife Inc (OTCBB:PHOT), Advaxis, Inc. (OTCBB:ADXS), Decision Diagnostics Corp (OTCBB:DECN), Affymax, Inc. (OTCMKTS:AFFY)
Growlife Inc (OTCBB:PHOT) increased +2.27% and closed at $0.0496 on a traded volume of 6.59 million shares, in comparison to 8.22 million shares of average trading volume. So far this year, the stock is up over +30.53%.
The company has a total market capitalization of $30.75 million and its total outstanding shares are 620.03 million. Growlife, Inc., through its subsidiaries, manufactures and markets horticulture and lifestyle products in the United States and internationally.
Why Should Investors Buy PHOT After The Recent Gain? Just Go Here and Find Out
Advaxis, Inc. (OTCBB:ADXS) plunged -11.28% and closed at $5.35 on a traded volume of 116,162 shares, whereas its average trading volume is 41,442 shares. In the last three months, the stock is up +9.46%. The Intra-day range for the stock is $4.40 and $6.05.
Advaxis, Inc., a clinical development stage biotechnology company, engages in the development of immunotherapies for cancer and infectious diseases. The company’s platform technology generates an immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.
Will ADXS Get Buyers Even After The Recent Rally? Find Out Here
Decision Diagnostics Corp (OTCBB:DECN) jumped up +10.78% and closed at $0.720. So far in three months, the stock is up +213.09%. The 52-week range for the stock is $0.05 and $0.73 and during the previous trading session the stock touched its highest price at $0.73. Its introductory price for the day was $0.63, with the overall traded volume of 909,844 shares.
Decision Diagnostics Corp. distributes prescription and non-prescription diagnostics, and home testing products in the United States. The company provides bulk prescription drugs on a wholesale basis; and distributes diabetes diagnostics and supplies.
For How Long DECN will Fight for Profitability? Read This Trend Analysis report
Affymax, Inc. (OTCMKTS:AFFY), after opening its shares at the price of $1.46, dropped -2.76% to close at $1.41 for the day. The stock moved on a traded volume of 629,045 shares, in comparison to 881,492 shares of average trading volume.
The 52-week range for the stock is $0.78 and $27.74 and during the previous trading session the stock touched its highest price at $1.48. Its introductory price for the day was $1.46. Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses.
Has AFFY Found The Bottom And Ready To Gain Momentum? Find Out Here
Our team of advisers here at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the CapitalEquityReport.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
Read Full Disclaimer at: http://capitalequityreport.com/about-us/disclaimer/
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)